ArticleAbdominal radiology (New York)2026
Hepatic fat fraction and lipid content of adrenal adenomas: insights from unenhanced CT.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenal incidentalomas (AI) are increasingly detected with the widespread use of abdominal computed tomography (CT). Although a relationship between AI, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease (MASLD) has been suggested, the evidence remains limited. PURPOSE: To investigate the relationship between hepatic fat fraction (HFF) and lipid content of adrenal adenomas using unenhanced CT.
methodsThis retrospective study included 176 patients (211 adrenal adenomas) diagnosed on unenhanced CT between September 2023 and June 2025. Adrenal adenomas were defined as lesions with attenuation ≤ 10 Hounsfield units (HU) or > 10 HU with stability on follow-up imaging. Hepatic attenuation was measured in three regions, and HFF was calculated with the formula: Fat fraction = - 0.58 × CT(HU) + 38.2. Patients were classified into four steatosis groups (normal, mild, moderate, severe). The fibrosis-4 index (FIB-4) was calculated to assess liver fibrosis. Statistical analyses included the Kruskal-Wallis H test for continuous variables, Chi-square test for categorical comparisons, and Pearson's correlation for associations.
resultsThe study population consisted of 59% females and 41% males, with a mean age of 59 years. Most adenomas were nonfunctioning (94%). Adenoma attenuation ranged from - 89 to + 28 HU. No significant correlation was found between adrenal adenoma attenuation and liver attenuation or HFF (p = .519 and p = .566, respectively). A weak negative correlation was observed between adenoma diameter and HFF (r = -.137, 95% CI: - 0.25 - - 0.02; p = .046). No association was found between hepatic steatosis and FIB-4 index.
conclusionThis study did not demonstrate a significant relationship between adrenal adenomas and MASLD. Hepatic steatosis and lipid content of adrenal adenomas appear to represent independent processes.
Indexed as
Identifiers
41284029What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.